A REVIEW OF REAL-WORLD EVIDENCE IN NON-ONCOLOGY SUBMISSIONS MADE TO FOUR HEALTH TECHNOLOGY ASSESSMENT (HTA) AGENCIES

被引：0
|
作者：
Balijepalli, C. [1 ]
Li, J. [1 ]
Ferrazzi, S. [2 ]
Mathers, E. [3 ]
Gullapalli, L. [1 ]
Awan, A. [3 ]
机构：
[1] Pharmalyt Grp, Vancouver, BC, Canada
[2] PharmaAccess, Waterdown, ON, Canada
[3] AbbVie Corp, St Laurent, PQ, Canada
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA50
引用
收藏
页码：S253 / S254
页数：2
相关论文
共 50 条
  • [1] Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies
    Harricharan, Sharada
    Curran, Eileen
    Lin, Huamao Mark
    Walton, Laura
    Gurjar, Khushboo
    Nguyen, Khoi
    Forsythe, Anna
    [J]. FUTURE ONCOLOGY, 2023, : 603 - 616
  • [2] The use of Real-World Data (RWD) by Health Technology Assessment (HTA) agencies
    Karen, K.
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2021, 31 : 218 - 218
  • [3] HOW HAS REAL-WORLD EVIDENCE BEEN LEVERAGED IN NON-ONCOLOGY SUBMISSIONS IN THE UK, FRANCE, AND GERMANY?
    Robert, A.
    Pardalidis, V
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S355 - S355
  • [4] EVALUATION OF THE EXTENT OF REAL-WORLD EVIDENCE (RWE) USED WITHIN HEALTH TECHNOLOGY APPRAISALS (HTA) IN ONCOLOGY: A COMPARATIVE STUDY OF SIX HTA AGENCIES
    Harricharan, S.
    Curran, E.
    Lin, H. M.
    Walton, L. J.
    Gurjar, K.
    Nguyen, K.
    Forsythe, A.
    [J]. VALUE IN HEALTH, 2021, 24 : S44 - S44
  • [5] Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies
    Makady, Amr
    ten Ham, Renske
    de Boer, Anthonius
    Hillege, Hans
    Klungel, Olaf
    Goettsch, Wim
    [J]. VALUE IN HEALTH, 2017, 20 (04) : 520 - 532
  • [6] Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
    Amr Makady
    Ard van Veelen
    Páll Jonsson
    Owen Moseley
    Anne D’Andon
    Anthonius de Boer
    Hans Hillege
    Olaf Klungel
    Wim Goettsch
    [J]. PharmacoEconomics, 2018, 36 : 359 - 368
  • [7] Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
    Makady, Amr
    van Veelen, Ard
    Jonsson, Pall
    Moseley, Owen
    D'Andon, Anne
    de Boer, Anthonius
    Hillege, Hans
    Klungel, Olaf
    Goettsch, Wim
    [J]. PHARMACOECONOMICS, 2018, 36 (03) : 359 - 368
  • [8] Using real-world data (RWD) in health technology assessment (HTA) practice: A comparative study of 5 HTA agencies
    Makady, Amr
    van Veelen, Ard
    Jonsson, Pall
    Moseley, Owen
    D'Andon, Anne
    de Boer, Anthonius
    Hillege, Hans
    Klungel, Olaf
    Goettsch, Wim
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 91 - 91
  • [9] USING REAL-WORLD DATA (RWD) IN HEALTH TECHNOLOGY ASSESSMENT (HTA) PRACTICE: A COMPARATIVE STUDY OF 5 HTA AGENCIES
    Makady, A.
    van Veelen, A.
    Jonsson, P.
    Moseley, O.
    D'Andon, A.
    de Boer, A.
    Hillege, J. L.
    Klungel, O.
    Goettsch, W.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A401 - A401
  • [10] POLICIES FOR USE OF REAL-WORLD DATA IN HEALTH TECHNOLOGY ASSESSMENT: A COMPARATIVE STUDY OF 6 HTA AGENCIES
    Makady, A.
    ten Ham, R.
    de Boer, A.
    Hillege, J. L.
    Klungel, O.
    Goettsch, W.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A501 - A502
12345